EA007219B1 - ПРОИЗВОДНЫЕ 3-ГЕТЕРОАРИЛ-3,5-ДИГИДРО-4-ОКСО-4Н-ПИРИДАЗИНО[4,5-b]ИНДОЛ-1-АЦЕТАМИДА, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВ - Google Patents

ПРОИЗВОДНЫЕ 3-ГЕТЕРОАРИЛ-3,5-ДИГИДРО-4-ОКСО-4Н-ПИРИДАЗИНО[4,5-b]ИНДОЛ-1-АЦЕТАМИДА, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВ Download PDF

Info

Publication number
EA007219B1
EA007219B1 EA200401146A EA200401146A EA007219B1 EA 007219 B1 EA007219 B1 EA 007219B1 EA 200401146 A EA200401146 A EA 200401146A EA 200401146 A EA200401146 A EA 200401146A EA 007219 B1 EA007219 B1 EA 007219B1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
group
hydrogen atom
general formula
compound
Prior art date
Application number
EA200401146A
Other languages
English (en)
Russian (ru)
Other versions
EA200401146A1 (ru
Inventor
Жак Фруассан
Бенуа Марабу
Франк Марге
Фредерик Пек
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of EA200401146A1 publication Critical patent/EA200401146A1/ru
Publication of EA007219B1 publication Critical patent/EA007219B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
EA200401146A 2002-04-03 2003-04-02 ПРОИЗВОДНЫЕ 3-ГЕТЕРОАРИЛ-3,5-ДИГИДРО-4-ОКСО-4Н-ПИРИДАЗИНО[4,5-b]ИНДОЛ-1-АЦЕТАМИДА, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВ EA007219B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204158A FR2838124B1 (fr) 2002-04-03 2002-04-03 Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
PCT/FR2003/001027 WO2003082874A2 (fr) 2002-04-03 2003-04-02 DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Publications (2)

Publication Number Publication Date
EA200401146A1 EA200401146A1 (ru) 2005-06-30
EA007219B1 true EA007219B1 (ru) 2006-08-25

Family

ID=28052083

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401146A EA007219B1 (ru) 2002-04-03 2003-04-02 ПРОИЗВОДНЫЕ 3-ГЕТЕРОАРИЛ-3,5-ДИГИДРО-4-ОКСО-4Н-ПИРИДАЗИНО[4,5-b]ИНДОЛ-1-АЦЕТАМИДА, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВ

Country Status (28)

Country Link
US (4) US7235554B2 (cg-RX-API-DMAC10.html)
EP (1) EP1492792B1 (cg-RX-API-DMAC10.html)
JP (2) JP4575670B2 (cg-RX-API-DMAC10.html)
KR (1) KR100975999B1 (cg-RX-API-DMAC10.html)
CN (2) CN100406459C (cg-RX-API-DMAC10.html)
AT (1) ATE321763T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003240930B2 (cg-RX-API-DMAC10.html)
BR (1) BR0309018A (cg-RX-API-DMAC10.html)
CA (1) CA2481460C (cg-RX-API-DMAC10.html)
CY (1) CY1104998T1 (cg-RX-API-DMAC10.html)
DE (1) DE60304327T2 (cg-RX-API-DMAC10.html)
DK (1) DK1492792T3 (cg-RX-API-DMAC10.html)
EA (1) EA007219B1 (cg-RX-API-DMAC10.html)
ES (1) ES2261940T3 (cg-RX-API-DMAC10.html)
FR (1) FR2838124B1 (cg-RX-API-DMAC10.html)
HR (1) HRP20040911B1 (cg-RX-API-DMAC10.html)
IL (2) IL164257A0 (cg-RX-API-DMAC10.html)
IS (1) IS2483B (cg-RX-API-DMAC10.html)
ME (2) MEP23708A (cg-RX-API-DMAC10.html)
MX (1) MXPA04009635A (cg-RX-API-DMAC10.html)
NO (1) NO329426B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ535741A (cg-RX-API-DMAC10.html)
PL (1) PL372617A1 (cg-RX-API-DMAC10.html)
PT (1) PT1492792E (cg-RX-API-DMAC10.html)
RS (1) RS51244B (cg-RX-API-DMAC10.html)
UA (1) UA77273C2 (cg-RX-API-DMAC10.html)
WO (1) WO2003082874A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200407945B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017932A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
JP2009504752A (ja) * 2005-08-19 2009-02-05 シェーリング コーポレイション 治療剤としての縮合三環式mGluR1アンタゴニスト
US20120041211A1 (en) * 2009-01-30 2012-02-16 Sythana Suresh Kumar Novel process for preparing carboxy-containing pyrazoleamido compounds 597
CN105330665B (zh) * 2015-11-04 2017-10-03 衡阳师范学院 一种抑制激肽释放酶klk7的化合物、制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2788776B1 (fr) * 1999-01-26 2001-02-23 Synthelabo Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique
FR2811897A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2811990A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo DERIVES DE 1-(4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1 -CARBONYL)PIPERAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2833953B1 (fr) * 2001-12-21 2004-12-03 Sanofi Synthelabo DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Also Published As

Publication number Publication date
IS7478A (is) 2004-09-30
AU2003240930B2 (en) 2009-07-30
RS51244B (sr) 2010-12-31
KR20040094904A (ko) 2004-11-10
NO329426B1 (no) 2010-10-18
EP1492792B1 (fr) 2006-03-29
US7405306B2 (en) 2008-07-29
US7235554B2 (en) 2007-06-26
JP4575670B2 (ja) 2010-11-04
KR100975999B1 (ko) 2010-08-17
CA2481460A1 (en) 2003-10-09
BR0309018A (pt) 2005-02-01
EP1492792A2 (fr) 2005-01-05
HK1074632A1 (zh) 2005-11-18
ES2261940T3 (es) 2006-11-16
UA77273C2 (en) 2006-11-15
JP2010248221A (ja) 2010-11-04
NZ535741A (en) 2007-03-30
DE60304327D1 (de) 2006-05-18
WO2003082874A2 (fr) 2003-10-09
JP2005527566A (ja) 2005-09-15
CN1656099A (zh) 2005-08-17
DK1492792T3 (da) 2006-08-14
DE60304327T2 (de) 2006-12-28
JP5277208B2 (ja) 2013-08-28
HK1102371A1 (en) 2007-11-16
US20070219202A1 (en) 2007-09-20
CN100406459C (zh) 2008-07-30
MXPA04009635A (es) 2005-07-13
PT1492792E (pt) 2006-08-31
MEP23708A (en) 2010-06-10
IS2483B (is) 2008-12-15
FR2838124B1 (fr) 2004-05-28
US7323467B2 (en) 2008-01-29
ZA200407945B (en) 2005-11-30
CN100543016C (zh) 2009-09-23
US20050124615A1 (en) 2005-06-09
CA2481460C (en) 2011-02-15
US20080076775A1 (en) 2008-03-27
CY1104998T1 (el) 2009-11-04
NO20044153L (no) 2004-12-27
HRP20040911A2 (en) 2004-12-31
US20080255129A1 (en) 2008-10-16
HRP20040911B1 (en) 2012-11-30
WO2003082874A3 (fr) 2004-04-01
PL372617A1 (en) 2005-07-25
CN1970538A (zh) 2007-05-30
EA200401146A1 (ru) 2005-06-30
ME00081B (me) 2010-10-10
AU2003240930A1 (en) 2003-10-13
FR2838124A1 (fr) 2003-10-10
ATE321763T1 (de) 2006-04-15
IL164257A (en) 2009-11-18
IL164257A0 (en) 2005-12-18
RS86904A (sr) 2006-12-15

Similar Documents

Publication Publication Date Title
JP5277208B2 (ja) 3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用
US8258168B2 (en) 2H or 3H-benzo[E]indazol-1-YL carbamate derivatives, the preparation and therapeutic use thereof
EA006251B1 (ru) ПРОИЗВОДНЫЕ 3-ГЕТЕРОАРИЛ-3,5-ДИГИДРО-4-ОКСО-4H-ПИРИДАЗИНО[4,5-b]ИНДОЛ-1-КАРБОКСАМИДА, ИХ ПОЛУЧЕНИЕ И ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
US20090215741A1 (en) 1H-Pyrimido[4,5-b]indole Derivatives, Their Preparation and Therapeutic Use
MXPA06009859A (en) 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof
HK1074632B (en) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
HK1102371B (en) Intermediate compound of 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives
HK1065792B (en) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU